Biomarker-based Immunoassays Market Size & Growth Forecast 2027–2036, By Segments (Sample, Product, Biomarker, End-use, Diseases), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Biomarker-based Immunoassays Market size was worth USD 5.69 billion in 2026 and is expected to grow at a 5.72% CAGR between 2027 and 2036, exceeding USD 9.92 billion by 2036. The industry revenue for 2027 is estimated at USD 5.97 billion.
Get more details on this report
Request Free Sample ReportBiomarker-based Immunoassays Market Intelligence Snapshot
Regional Market Dynamics
- North America held 51.94% of the market in 2026, supported by advanced diagnostic infrastructure, biomedical research capabilities, and precision medicine adoption across oncology, infectious diseases, and other clinical applications.
- Asia Pacific is growing fastest as improving healthcare infrastructure, expanding laboratory capabilities, and rising demand for early disease detection encourage investment in biomarker testing and precision medicine applications.
Segment Momentum
- Reagents and kits accounted for 45.38% of the market in 2026, supported by recurring laboratory demand across clinical testing, pharmaceutical research, and diagnostics, while ready-to-use formats simplify assay preparation and improve workflow efficiency.
- Efficacy and pharmacodynamic biomarkers held 37.93% of the market in 2026 and are expected to grow fastest, as pharmaceutical developers increasingly use measurable biological responses to evaluate treatment activity and support evidence-based drug development.
Market Expansion Drivers
- Increased biomarker testing in diagnostics.
- Automation in immunoassay platforms.
- Novel biomarker validation.
Leading Market Participants
- Key companies in the biomarker-based immunoassays market include Thermo Fisher Scientific (USA), Roche Diagnostics (Switzerland), Abbott (USA), Bio-Rad Laboratories (USA), Siemens Healthineers (Germany), Danaher (USA), PerkinElmer (USA), Merck Millipore (Merck KGaA) (Germany), Beckman Coulter (USA), Quanterix Corporation (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 5.69 billion
- 2027 Estimated Market Size: USD 5.97 billion
- Projected Market Size: USD 9.92 billion by 2036
- Growth Forecast: 5.72% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Sample (Blood) | Product (Reagent & Kits) | Biomarker (Efficacy & Pharmacodynamic Biomarkers) | End-use (Hospitals & Clinics) | Diseases (Cancer)
- Emerging Opportunity Segment: Sample (Blood) | Product (Reagent & Kits) | Biomarker (Efficacy & Pharmacodynamic Biomarkers) | End-use (Hospitals & Clinics) | Diseases (Cancer)
Market Growth Drivers and Industry Trends
Increased biomarker testing in diagnostics
The increasing use of biomarker testing in diagnostic workflows is driving demand for biomarker-based immunoassays across clinical and laboratory settings. Biomarkers provide valuable insights into disease detection, progression, and treatment response, supporting more targeted and personalized diagnostic approaches. Growing awareness of early disease identification and the expanding use of diagnostic testing for complex and chronic conditions are further encouraging the adoption of immunoassay-based technologies. In addition, the integration of biomarker analysis into routine laboratory testing is strengthening the role of immunoassays in modern diagnostic workflows.
Automation in immunoassay platforms
The growing adoption of automation in immunoassay platforms is supporting market expansion by improving laboratory efficiency, workflow consistency, and testing throughput. Automated systems can streamline sample handling, reagent management, assay processing, and result generation, reducing the reliance on manual intervention and helping laboratories manage increasing testing workloads. Automation also supports standardized testing procedures and improves operational reproducibility, making advanced immunoassay platforms increasingly attractive for diagnostic laboratories and research environments. Furthermore, integration with broader laboratory automation systems is enabling more efficient end-to-end diagnostic workflows.
Novel biomarker validation
The continued discovery and validation of novel biomarkers is creating new opportunities for biomarker-based immunoassay development. Advances in disease research are identifying biological indicators that can support improved diagnosis, disease classification, prognosis, and monitoring of therapeutic responses. Validating these biomarkers for reliable clinical use encourages the development of specialized immunoassays capable of detecting and quantifying emerging targets. In addition, growing emphasis on precision medicine is increasing the need for validated biomarkers that can support more individualized approaches to disease management and treatment selection.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increased biomarker testing in diagnostics | 1.8% | Short term (≤ 2 yrs) | North America; Europe | High | Moderate |
| Automation in immunoassay platforms | 1.4% | Medium term (2–5 yrs) | Europe; Asia Pacific | Medium | Moderate |
| Novel biomarker validation | 1% | Long term (5+ yrs) | North America; Europe | Medium | Slow |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America held the largest share of 51.94% share in 2026 in the biomarker-based immunoassays market, backed by advanced diagnostic infrastructure, strong biomedical research capabilities, and widespread adoption of precision medicine. Healthcare providers increasingly use biomarker-based immunoassays for disease detection, therapeutic monitoring, and clinical decision-making, creating sustained demand for sensitive and reliable testing technologies. The region benefits from established laboratory networks, increasing investment in biomarker research, and growing utilization of personalized healthcare approaches. Expanding applications across oncology, infectious diseases, autoimmune disorders, and other diagnostic areas further support market development.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing region in the biomarker-based immunoassays market, driven by improving healthcare infrastructure, rising demand for advanced diagnostics, and increasing awareness of early disease detection. Expanding laboratory capabilities and greater access to modern diagnostic technologies are enabling broader adoption across hospitals, research institutions, and diagnostic centers. Growing healthcare expenditure and the increasing prevalence of chronic and complex diseases are encouraging investment in biomarker testing. In addition, expanding research activity and the adoption of precision medicine approaches are creating new opportunities for immunoassay technologies across clinical and research applications.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Precision Diagnostics AdoptionThe U.S. continues to prioritize biomarker-based immunoassays across oncology, immunology, and precision medicine workflows, supported by sophisticated laboratory infrastructure and clinical research activity. Commercial opportunities center on multiplexing, high-sensitivity platforms, and assays that can translate biomarkers into actionable diagnostic or treatment decisions.
Germany 🇩🇪
Clinical Lab IntegrationGermany’s established diagnostic laboratory network supports adoption of biomarker-based immunoassays, particularly where validated assays can strengthen disease stratification and therapy monitoring. Market priorities include analytical reliability, workflow automation, and integration of biomarker testing with hospital and laboratory information systems.
Japan 🇯🇵
Aging-Care DiagnosticsJapan presents strong practical demand for biomarker-based immunoassays that support earlier disease detection, chronic-condition monitoring, and personalized treatment decisions. Suppliers are likely to emphasize compact automation, high-throughput laboratory workflows, and assays suited to hospitals and diagnostic settings managing an aging patient population.
South Korea 🇰🇷
Advanced Biomarker PlatformsSouth Korea is strengthening biomarker testing capabilities through advanced diagnostics, biotechnology development, and precision-medicine applications. Commercial priorities include multiplex immunoassays, companion-diagnostic applications, and scalable platforms that can support both clinical laboratories and the country’s expanding biomedical research ecosystem.
France 🇫🇷
Translational DiagnosticsFrance’s biomarker-based immunoassay demand is closely connected with clinical research, hospital diagnostics, and personalized medicine initiatives. Opportunities favor validated assays capable of supporting oncology and chronic-disease applications, alongside technologies that improve laboratory standardization, reproducibility, and integration into routine clinical workflows.
Italy 🇮🇹
Hospital Diagnostics ExpansionItaly’s market priorities center on strengthening biomarker testing within hospitals and specialized diagnostic laboratories, particularly for oncology and chronic disease management. Suppliers can differentiate through reliable automated platforms, accessible testing workflows, and assays that help clinicians incorporate biomarker information into routine diagnostic pathways.
Biomarker-based Immunoassays Market Share (%), by Sample, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportSample Segment Analysis: Blood (Largest & Fastest-Growing Segment)
The blood sample segment accounted for the largest share of 57.73% in the biomarker-based immunoassays market in 2026 and is also expected to experience the fastest growth. Blood remains a widely used biological sample for biomarker analysis because it provides access to circulating proteins, hormones, antibodies, metabolites, and other measurable indicators associated with disease status and therapeutic response. The relatively established procedures for blood collection, processing, storage, and laboratory analysis support its extensive use across clinical diagnostics, drug development, disease monitoring, and research applications. Blood-based immunoassays can also support the evaluation of biomarkers associated with disease progression and treatment response, making them valuable across a broad range of healthcare applications. Continued expansion of precision medicine, increasing demand for minimally complex laboratory workflows, and growing biomarker research are expected to reinforce the importance of blood samples in biomarker-based immunoassay applications.
Product Segment Analysis: Reagent & Kits (Largest & Fastest-Growing Segment)
The reagent & kits segment represented the largest share of 45.38% in the biomarker-based immunoassays market in 2026 and is also projected to register the fastest growth. Reagents and kits form the core consumable components required to perform immunoassay procedures, enabling the detection and measurement of specific biomarkers in biological samples. Their broad application across clinical testing, pharmaceutical research, academic studies, and diagnostic laboratories creates recurring demand as immunoassay workflows require regular supplies of assay-specific materials. Increasing adoption of standardized and ready-to-use testing formats is also improving laboratory efficiency by simplifying assay preparation and reducing procedural complexity. As biomarker discovery expands and immunoassay-based testing becomes increasingly integrated into diagnostic and drug development workflows, demand for specialized reagents and kits is expected to continue strengthening.
Biomarker Segment Analysis: Efficacy & Pharmacodynamic Biomarkers (Largest & Fastest-Growing Segment)
The efficacy & pharmacodynamic biomarkers segment accounted for the largest share of 37.93% in the biomarker-based immunoassays market in 2026 and is also expected to register the fastest growth. These biomarkers are important for evaluating whether a therapeutic intervention is producing the intended biological effect and for understanding changes that occur following treatment exposure. Their application can support drug development by helping researchers assess treatment activity, monitor biological responses, and identify relationships between therapeutic intervention and measurable changes in disease-related pathways. Increasing emphasis on evidence-based drug development and more precise evaluation of treatment response is encouraging the use of biomarkers throughout pharmaceutical research and clinical development. As personalized treatment approaches and biomarker-guided development strategies gain broader adoption, efficacy and pharmacodynamic biomarkers are expected to become increasingly important for immunoassay-based testing.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Sample | Blood, Tissue, Urine, Saliva | Blood | Blood |
| Product | Consumables, Instruments/ Analyzers, Reagent & Kits, Services | Reagent & Kits | Reagent & Kits |
| Biomarker | Safety & Toxicity Biomarkers, Efficacy & Pharmacodynamic Biomarkers, Predictive & Prognostic Biomarkers, Surrogate/Exploratory Biomarkers | Efficacy & Pharmacodynamic Biomarkers | Efficacy & Pharmacodynamic Biomarkers |
| End-use | Hospitals & Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others | Hospitals & Clinics | Hospitals & Clinics |
| Diseases | Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Others | Cancer | Cancer |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Competitive positioning in the biomarker-based immunoassays market relies on analytical reliability, testing efficiency, and the strength of evidence supporting specific applications. Sensitivity and specificity remain foundational because detection limits and cross-reactivity directly affect result quality and interpretation. Multiplexing and high-throughput capabilities can improve laboratory efficiency and expand biomarker profiling, but suppliers must manage signal interference and maintain consistency across analytes. Point-of-care adaptation introduces a different set of priorities, including rapid results, portability, and dependable performance under less controlled testing conditions. Partnerships supporting biomarker discovery and validation can further strengthen product development by generating evidence of clinical relevance and reproducibility. However, commercial success depends on translating these capabilities into validated assays suited to clearly defined research, diagnostic, or monitoring needs.
Top players in the biomarker-based immunoassays market:
- Thermo Fisher Scientific (USA)
- Roche Diagnostics (Switzerland)
- Abbott (USA)
- Bio-Rad Laboratories (USA)
- Siemens Healthineers (Germany)
- Danaher (USA)
- PerkinElmer (USA)
- Merck Millipore (Merck KGaA) (Germany)
- Beckman Coulter (USA)
- Quanterix Corporation (USA)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific (USA) | |||||||
| Roche Diagnostics (Switzerland) | |||||||
| Abbott (USA) | |||||||
| Bio-Rad Laboratories (USA) | |||||||
| Siemens Healthineers (Germany) | |||||||
| Danaher (USA) | |||||||
| PerkinElmer (USA) | |||||||
| Merck Millipore (Merck KGaA) (Germany) | |||||||
| Beckman Coulter (USA) | |||||||
| Quanterix Corporation (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Labcorp | October 2023 | Labcorp launched a tri-biomarker blood test for the diagnosis of Alzheimer’s disease. The development expands the use of blood-based biomarker testing in neurodegenerative disease diagnostics and strengthens Labcorp’s diagnostic testing capabilities within an emerging application area for biomarker-based immunoassays. |
| Mindray | October 2023 | Mindray launched high-sensitivity NT-proBNP and troponin I (hs-cTnI) cardiac biomarkers, expanding its product portfolio for cardiac biomarker testing. The assays are intended for use in the management and diagnosis of cardiovascular diseases, strengthening Mindray’s position in biomarker-based diagnostic testing for cardiac applications. |
| Quest Diagnostics | August 2023 | Quest Diagnostics partnered with Envision Sciences for the commercial launch of a novel prostate cancer biomarker test designed to identify severe and aggressive forms of the disease. The partnership supports commercialization of biomarker-based diagnostic testing and expands the application of biomarker assays in cancer detection and clinical decision-making. |
| Quanterix | July 2023 | Quanterix launched LucentAD, a blood-based biomarker test designed to assist in the diagnosis of Alzheimer’s disease. The commercialization adds a biomarker-based blood testing option for Alzheimer’s diagnosis and broadens the application of blood-based biomarker technologies in neurological disease assessment. |
| Roche | July 2022 | The U.S. FDA granted Breakthrough Device Designation to Roche’s Elecsys Amyloid Plasma Panel for the early detection of Alzheimer’s disease. The designation made Roche the first in vitro diagnostics manufacturer to receive Breakthrough Device Designation for a blood-based Alzheimer’s biomarker test, supporting advancement of blood-based biomarker diagnostics. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Biomarker-based Immunoassays Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Assay Format | ELISA, Immunofluorescence Assays, Chemiluminescent Immunoassays, Lateral Flow Immunoassays, Other Immunoassay Formats |
| Multiplexing Capability | Singleplex Assays, Low-Plex Assays, High-Plex Assays |
| Testing Purpose | Drug Discovery & Development, Clinical Diagnostics, Disease Monitoring, Personalized Medicine & Companion Diagnostics, Research Applications |
Biomarker-based Immunoassays Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Companion Diagnostic Adoption Pathways |
|
| Biomarker Validation Economics |
|
| Biopharma Biomarker Testing Strategy |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How much is the biomarker-based immunoassays market worth?
How much is the biomarker-based immunoassays industry expected to grow by 2036?
How is the expansion of biomarker testing reshaping demand for immunoassay platforms?
Why is automation becoming strategically important in biomarker-based immunoassay workflows?
Why do reagent and kit products lead the biomarker-based immunoassays market?
How are efficacy and pharmacodynamic biomarkers influencing immunoassay demand?
Why does North America dominate the biomarker-based immunoassays market?
How is Asia Pacific creating new opportunities in the biomarker-based immunoassays market?
What are the prominent companies operating in the biomarker-based immunoassays landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook